NurExone Biologic Inc.
NRXBF
$0.47
$0.025.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.02% | 5.75% | 17.35% | 41.77% | 43.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.92% | 10.21% | 26.23% | 52.61% | 52.69% |
| Operating Income | 0.92% | -10.21% | -26.23% | -52.61% | -52.69% |
| Income Before Tax | 0.17% | -11.61% | -26.59% | -54.35% | -52.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.17% | -11.61% | -26.59% | -54.35% | -52.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.17% | -11.61% | -26.59% | -54.35% | -52.58% |
| EBIT | 0.92% | -10.21% | -26.23% | -52.61% | -52.69% |
| EBITDA | 2.09% | -8.91% | -24.56% | -50.95% | -51.71% |
| EPS Basic | 17.33% | 9.22% | -2.53% | -19.37% | -10.04% |
| Normalized Basic EPS | 17.34% | 9.33% | -2.22% | -19.34% | -10.04% |
| EPS Diluted | 17.33% | 9.22% | -2.53% | -19.37% | -10.04% |
| Normalized Diluted EPS | 17.34% | 9.33% | -2.22% | -19.34% | -10.04% |
| Average Basic Shares Outstanding | 21.45% | 23.98% | 25.46% | 30.85% | 36.62% |
| Average Diluted Shares Outstanding | 21.45% | 23.98% | 25.46% | 30.85% | 36.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |